To stop or not to stop an asthma biologic, that is the question.

Authors :: Philipenko BS
Davis B
Cockcroft DW
Source :: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2024 Sep; Vol. 133 (3), pp. 236-237.
Publication Year :: 2024
Abstract: Competing Interests: Disclosures Dr Philipenko has received speaking honoraria from Covis pharma, GlaxoSmithKline, AstraZeneca, and Regeneron Pharmaceuticals and fees from AstraZeneca and Sanofi for serving on advisory boards. Dr Cockcroft and Dr Davis have no conflicts of interest to report.

Subjects :: Humans
Biological Products therapeutic use
Asthma drug therapy
Anti-Asthmatic Agents therapeutic use

Language :: English
ISSN :: 1534-4436
Volume :: 133
Issue :: 3
Database :: MEDLINE
Journal :: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Publication Type :: Academic Journal
Accession number :: 39179302
Full Text :: https://doi.org/10.1016/j.anai.2024.06.012